↓ Skip to main content

Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus

Overview of attention for article published in PharmacoEconomics - Open, July 2019
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (62nd percentile)
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter
7 X users
facebook
2 Facebook pages

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
61 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
Published in
PharmacoEconomics - Open, July 2019
DOI 10.1007/s41669-019-0171-y
Pubmed ID
Authors

Margarita Capel, Andreea Ciudin, María Mareque, Raquel María Rodríguez-Rincón, Susana Simón, Itziar Oyagüez

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 61 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 13%
Student > Ph. D. Student 7 11%
Student > Doctoral Student 4 7%
Other 4 7%
Student > Master 4 7%
Other 10 16%
Unknown 24 39%
Readers by discipline Count As %
Medicine and Dentistry 16 26%
Pharmacology, Toxicology and Pharmaceutical Science 7 11%
Unspecified 2 3%
Nursing and Health Professions 2 3%
Economics, Econometrics and Finance 2 3%
Other 6 10%
Unknown 26 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 July 2020.
All research outputs
#7,277,820
of 23,152,542 outputs
Outputs from PharmacoEconomics - Open
#141
of 333 outputs
Outputs of similar age
#128,715
of 346,292 outputs
Outputs of similar age from PharmacoEconomics - Open
#9
of 30 outputs
Altmetric has tracked 23,152,542 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 333 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 346,292 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.